5.13
Taysha Gene Therapies Inc stock is traded at $5.13, with a volume of 2.64M.
It is up +5.29% in the last 24 hours and up +67.37% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$4.88
Open:
$4.88
24h Volume:
2.64M
Relative Volume:
0.47
Market Cap:
$1.40B
Revenue:
$8.10M
Net Income/Loss:
$-92.72M
P/E Ratio:
-15.09
EPS:
-0.34
Net Cash Flow:
$-82.52M
1W Performance:
+16.25%
1M Performance:
+67.37%
6M Performance:
+312.71%
1Y Performance:
+155.63%
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TSHA
Taysha Gene Therapies Inc
|
5.13 | 1.33B | 8.10M | -92.72M | -82.52M | -0.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.33 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
800.99 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-11-25 | Initiated | BofA Securities | Buy |
Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
Apr-09-24 | Initiated | Piper Sandler | Overweight |
Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
Mar-09-22 | Initiated | Robert W. Baird | Outperform |
Mar-01-22 | Initiated | Wells Fargo | Overweight |
Feb-18-22 | Initiated | SMBC Nikko | Outperform |
Dec-16-21 | Initiated | Guggenheim | Buy |
Jul-16-21 | Initiated | Needham | Buy |
Jun-24-21 | Initiated | Truist | Buy |
Jun-15-21 | Initiated | BTIG Research | Buy |
Jun-09-21 | Initiated | Wedbush | Outperform |
Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
May-11-21 | Resumed | Jefferies | Buy |
Feb-24-21 | Initiated | William Blair | Outperform |
Jan-05-21 | Initiated | Oppenheimer | Outperform |
Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
Oct-19-20 | Initiated | Goldman | Buy |
Oct-19-20 | Initiated | Jefferies | Buy |
Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Earnings visualization tools for Taysha Gene Therapies Inc.Weekly Trading Summary & Fast Entry Momentum Trade Alerts - newser.com
Why Taysha Gene Therapies Inc. is moving today2025 Price Action Summary & Weekly High Return Forecasts - newser.com
Has Taysha Gene Therapies Inc. formed a bullish divergenceJuly 2025 Decliners & Low Drawdown Investment Strategies - newser.com
Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory - MSN
Tick level data insight on Taysha Gene Therapies Inc. volatilityJuly 2025 Sentiment & Free Reliable Trade Execution Plans - newser.com
What MACD and RSI say about Taysha Gene Therapies Inc.2025 Volume Leaders & Smart Allocation Stock Tips - newser.com
Can Taysha Gene Therapies Inc. stock hit record highs again2025 Volatility Report & Verified Entry Point Signals - newser.com
Is Taysha Gene Therapies Inc. trending in predictive chart modelsPortfolio Return Report & Consistent Income Trade Ideas - newser.com
Weiss Ratings Reiterates Sell (D-) Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price - Markets Mojo
Taysha Gene Therapies (TSHA) Reveals Enhanced Trial Results for Rett Syndrome - GuruFocus
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - The Manila Times
Taysha Gene Therapies Presents New Supplemental Data - GlobeNewswire
Will Taysha Gene Therapies Inc. stock continue dividend increasesMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Analyzing net buyer seller activity in Taysha Gene Therapies Inc.Weekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
Visual analytics tools that track Taysha Gene Therapies Inc. performanceEarnings Beat & Daily Technical Stock Forecast Reports - newser.com
Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure - Markets Mojo
Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Taysha soars on FDA breakthrough therapy status for lead asset - MSN
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 4.9%Time to Sell? - MarketBeat
Taysha Gene Therapies Hits New 52-Week High at $5.40 - Markets Mojo
Taysha Gene Therapies: Breakthrough Rett Program With BLA Acceleration Potential (TSHA) - Seeking Alpha
Will Taysha Gene Therapies Inc. stock maintain growth story2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
How to interpret RSI for Taysha Gene Therapies Inc. stockWeekly Trade Analysis & Low Volatility Stock Recommendations - newser.com
Taysha Snags FDA Breakthrough Therapy Designation for Rett Syndrome Gene Therapy TSHA-102 - CGTLive®
How Recent Developments Are Rewriting the Story for Taysha Gene Therapies - Yahoo Finance
Taysha Gene Therapies (TSHA) Gets a Buy from Canaccord Genuity - The Globe and Mail
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Needham & Company LLC Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Best Small Cap Stocks To Add to Your Watchlist – October 2nd - Defense World
Taysha Gene Therapies stock hits 52-week high at 5.05 USD - Investing.com Nigeria
1.29M-option grant: Taysha grants 1,289,600 stock options at $3.18, 4-yr vesting under Nasdaq rule - Stock Titan
US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy - insights.citeline.com
Taysha Gene Therapies (NASDAQ:TSHA) Sees Unusually-High Trading Volume After Analyst Upgrade - MarketBeat
BMO Capital Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
A Quick Look at Today's Ratings for Taysha Gene Therapies(TSHA.US), With a Forecast Between $8 to $14 - 富途牛牛
Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy | FinancialCont - FinancialContent
Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals - Stocktwits
Could Taysha's FDA Alignment Fast-Track Its BLA Submission? - RTTNews
Robert W. Baird Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price - Defense World
Analyzing drawdowns of Taysha Gene Therapies Inc. with statistical toolsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Taysha Gene Therapies Target of Unusually High Options Trading (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Taysha Gene Therapies Inc Stock (TSHA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Option Exercise |
0.70 |
41,150 |
28,760 |
1,206,439 |
Nagendran Sukumar | President and Head of R&D |
Sep 10 '25 |
Sale |
3.23 |
200,000 |
646,000 |
1,006,439 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):